Celyad and Institut Curie in NKR-T collaboration
22 March 2016 | By Victoria White
Celyad is teaming up with the Inserm Unit of Institut Curie in Paris, France, to further develop its NKR-T pipeline in cellular immunotherapies for cancer...
List view / Grid view
22 March 2016 | By Victoria White
Celyad is teaming up with the Inserm Unit of Institut Curie in Paris, France, to further develop its NKR-T pipeline in cellular immunotherapies for cancer...
2 March 2016 | By Victoria White
The US Patent 9,273,283 is the second patent of Celyad allogeneic intellectual property portfolio that is awarded by the USPTO...
23 February 2016 | By Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad
Natural killer receptor T-cells have the potential to become a real game changing treatment for patients with cancer. Here, Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad, discusses this new cancer fighting technology...
26 October 2015 | By Victoria White
The US 9,181,527 Celyad Allogeneic Patent significantly strengthens Celyad’s patent portfolio in the CAR T-Cell field...
21 April 2015 | By Victoria White
The first patient enrolled in a Phase I clinical trial evaluating the safety and feasibility of NKG2D CAR T-cell therapy has been infused...
8 April 2015 | By Victoria White
Cardio3 has received a Notice of Allowance from the USPTO for a patent application covering TCR-deficient T-Cells which are engineered to express a CAR...
6 November 2014 | By Cardio3 BioSciences
Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces that it has acquired U.S.-based CorQuest Medical Inc. CorQuest Medical specializes in the development of innovative devices and technologies for cardiac surgery...
1 October 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces that it has recently increased its business development activities, building on its core expertise in cellular therapies and in cardiovascular diseases...